222 related articles for article (PubMed ID: 33642229)
1. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer.
Feldman AS; Kulkarni GS; Bivalacqua TJ; Black PC; Delacroix S; Lerner SP; Kamat AM; Kassouf W
Urol Oncol; 2022 Oct; 40(10):442-450. PubMed ID: 33642229
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
3. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
4. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
5. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
6. Trimodal therapy for muscle-invasive bladder cancer.
Mathes J; Rausch S; Todenhöfer T; Stenzl A
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1219-1229. PubMed ID: 30324833
[TBL] [Abstract][Full Text] [Related]
7. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?
Mathieu R; Lucca I; Klatte T; Babjuk M; Shariat SF
Curr Opin Urol; 2015 Sep; 25(5):476-82. PubMed ID: 26125510
[TBL] [Abstract][Full Text] [Related]
8. Organ preservation approaches with radiation therapy in muscle-invasive bladder carcinoma.
Liu MC; Zietman AL; Shipley WU
Ann Acad Med Singap; 1996 May; 25(3):441-7. PubMed ID: 8876914
[TBL] [Abstract][Full Text] [Related]
9. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.
Eswara JR; Efstathiou JA; Heney NM; Paly J; Kaufman DS; McDougal WS; McGovern F; Shipley WU
J Urol; 2012 Feb; 187(2):463-8. PubMed ID: 22177159
[TBL] [Abstract][Full Text] [Related]
10. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Konieczkowski DJ; Efstathiou JA; Mouw KW
Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151
[TBL] [Abstract][Full Text] [Related]
11. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
El-Achkar A; Souhami L; Kassouf W
Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
[TBL] [Abstract][Full Text] [Related]
12. Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer.
Ericson KJ; Murthy PB; Bryk DJ; Ramkumar RR; Broughman JR; Khanna A; Mian OY; Campbell SC
Clin Adv Hematol Oncol; 2019 Dec; 17(12):697-707. PubMed ID: 31851158
[TBL] [Abstract][Full Text] [Related]
13. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer.
Ballas L; Singh P; Lerner SP
Urol Oncol; 2023 Jan; 41(1):35-38. PubMed ID: 33153882
[TBL] [Abstract][Full Text] [Related]
14. [Bladder-sparing trimodal therapy for muscle invasive bladder cancer].
Khalifa J; Roumiguié M; Pouessel D; Sargos P
Cancer Radiother; 2022 Oct; 26(6-7):771-778. PubMed ID: 35970682
[TBL] [Abstract][Full Text] [Related]
15. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
Jiang DM; Chung P; Kulkarni GS; Sridhar SS
Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
[TBL] [Abstract][Full Text] [Related]
16. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
[TBL] [Abstract][Full Text] [Related]
18. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
[TBL] [Abstract][Full Text] [Related]
19. Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.
Zehnder P; Thalmann GN
Curr Opin Urol; 2013 Sep; 23(5):423-8. PubMed ID: 23880740
[TBL] [Abstract][Full Text] [Related]
20. The Legacy of RTOG/NRG Protocols in Shaping Current Bladder Preservation Therapy in North America.
Kamran SC; Efstathiou JA
Semin Radiat Oncol; 2023 Jan; 33(1):26-34. PubMed ID: 36517191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
